109 related articles for article (PubMed ID: 21288302)
1. A novel ErbB2 epitope targeted by human antitumor immunoagents.
Troise F; Monti M; Merlino A; Cozzolino F; Fedele C; Russo Krauss I; Sica F; Pucci P; D'Alessio G; De Lorenzo C
FEBS J; 2011 Apr; 278(7):1156-66. PubMed ID: 21288302
[TBL] [Abstract][Full Text] [Related]
2. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.
Troise F; Cafaro V; Giancola C; D'Alessio G; De Lorenzo C
FEBS J; 2008 Oct; 275(20):4967-79. PubMed ID: 18795950
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents.
Riccio G; Esposito G; Leoncini E; Contu R; Condorelli G; Chiariello M; Laccetti P; Hrelia S; D'Alessio G; De Lorenzo C
FASEB J; 2009 Sep; 23(9):3171-8. PubMed ID: 19417081
[TBL] [Abstract][Full Text] [Related]
4. Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.
Gelardi T; Damiano V; Rosa R; Bianco R; Cozzolino R; Tortora G; Laccetti P; D'Alessio G; De Lorenzo C
Br J Cancer; 2010 Feb; 102(3):513-9. PubMed ID: 20051960
[TBL] [Abstract][Full Text] [Related]
5. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
De Lorenzo C; Troise F; Cafaro V; D'Alessio G
Br J Cancer; 2007 Nov; 97(10):1354-60. PubMed ID: 17923870
[TBL] [Abstract][Full Text] [Related]
7. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
[TBL] [Abstract][Full Text] [Related]
8. Biological properties of a human compact anti-ErbB2 antibody.
De Lorenzo C; Cozzolino R; Carpentieri A; Pucci P; Laccetti P; D'Alessio G
Carcinogenesis; 2005 Nov; 26(11):1890-5. PubMed ID: 15930029
[TBL] [Abstract][Full Text] [Related]
9. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
Fedele C; Riccio G; Coppola C; Barbieri A; Monti MG; Arra C; Tocchetti CG; D'Alessio G; Maurea N; De Lorenzo C
Breast Cancer Res Treat; 2012 Jun; 133(2):511-21. PubMed ID: 21947749
[TBL] [Abstract][Full Text] [Related]
10. Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.
De Lorenzo C; D'Alessio G
FEBS J; 2009 Mar; 276(6):1527-35. PubMed ID: 19220462
[TBL] [Abstract][Full Text] [Related]
11. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
[TBL] [Abstract][Full Text] [Related]
12. Effects of a human compact anti-ErbB2 antibody on prostate cancer.
Malara AE; Fedele C; Aloj L; Arra C; Laccetti P; D'Alessio G; De Lorenzo C
Oncol Rep; 2012 Jul; 28(1):297-302. PubMed ID: 22505344
[TBL] [Abstract][Full Text] [Related]
13. Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitory monoclonal antibodies.
Wang JN; Feng JN; Yu M; Xu M; Shi M; Zhou T; Yu XD; Shen BF; Guo N
Mol Immunol; 2004 Feb; 40(13):963-9. PubMed ID: 14725792
[TBL] [Abstract][Full Text] [Related]
14. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
15. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.
Neve RM; Nielsen UB; Kirpotin DB; Poul MA; Marks JD; Benz CC
Biochem Biophys Res Commun; 2001 Jan; 280(1):274-9. PubMed ID: 11162510
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
[TBL] [Abstract][Full Text] [Related]
19. De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure.
Wang J; Feng J; Shi M; Qian L; Chen L; Yu M; Xu R; Shen B; Guo N
Mol Immunol; 2008 Jan; 45(1):106-16. PubMed ID: 17572496
[TBL] [Abstract][Full Text] [Related]
20. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition.
Riemer AB; Kraml G; Scheiner O; Zielinski CC; Jensen-Jarolim E
Mol Immunol; 2005 May; 42(9):1121-4. PubMed ID: 15829301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
